BioNTech SE (NASDAQ:BNTX) Expected to Earn FY2024 Earnings of ($3.71) Per Share

BioNTech SE (NASDAQ:BNTX) – Equities research analysts at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for BioNTech in a research report issued to clients and investors on Tuesday, August 27th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($3.71) for the year, down from their previous estimate of ($3.66). HC Wainwright has a “Buy” rating and a $113.00 price objective on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($2.04) per share. HC Wainwright also issued estimates for BioNTech’s Q1 2025 earnings at ($2.39) EPS, Q2 2025 earnings at ($2.40) EPS and FY2025 earnings at ($3.15) EPS.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a return on equity of 0.55% and a net margin of 4.01%. The company had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. During the same period in the prior year, the firm posted ($0.86) EPS. The firm’s revenue for the quarter was down 23.3% on a year-over-year basis.

Several other research analysts have also recently issued reports on the company. Deutsche Bank Aktiengesellschaft upgraded BioNTech from a “hold” rating to a “buy” rating and set a $95.00 price objective for the company in a research note on Wednesday, August 7th. JPMorgan Chase & Co. decreased their price objective on shares of BioNTech from $94.00 to $91.00 and set an “underweight” rating for the company in a research note on Thursday, August 15th. HSBC raised shares of BioNTech from a “hold” rating to a “buy” rating in a report on Friday, August 2nd. BMO Capital Markets lowered their price target on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a report on Tuesday, May 7th. Finally, Evercore ISI began coverage on BioNTech in a research note on Tuesday, May 14th. They set an “inline” rating and a $100.00 price objective for the company. One analyst has rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $109.09.

BioNTech Stock Performance

Shares of BNTX stock opened at $88.22 on Thursday. The business has a fifty day moving average of $84.02 and a 200 day moving average of $89.34. BioNTech has a 1 year low of $76.53 and a 1 year high of $125.83. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.38 and a quick ratio of 11.16. The firm has a market capitalization of $20.97 billion, a price-to-earnings ratio of 176.44 and a beta of 0.23.

Institutional Trading of BioNTech

A number of institutional investors and hedge funds have recently modified their holdings of the stock. CWM LLC boosted its stake in BioNTech by 657.6% during the 4th quarter. CWM LLC now owns 250 shares of the company’s stock worth $26,000 after purchasing an additional 217 shares during the last quarter. GAMMA Investing LLC lifted its stake in BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after purchasing an additional 150 shares in the last quarter. Frazier Financial Advisors LLC acquired a new position in shares of BioNTech during the 4th quarter worth approximately $30,000. First Horizon Advisors Inc. purchased a new stake in shares of BioNTech in the fourth quarter valued at approximately $38,000. Finally, Covestor Ltd increased its holdings in shares of BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.